12.14.22
Kerry, a global taste and nutrition company, has entered into a new commercial agreement with Japan-based Kameda Seika to market and distribute the company’s rice-derived postbiotic, Lactobacillus K-1 (Lactobacillus casei subsp. 327) in the Americas and Europe.
Postbiotics, the byproducts of inanimate microorganisms, offer similar benefits as probiotics, but are more heat- and acid-stable.
Kameda Seika is a global rice cracker company which has researched rice-based lactobacillus for over 25 years. The company’s postbiotic ingredient has been evidenced to improve measures of digestive and skin health and can be used in a variety of food, beverages, and supplements. Kerry will drive the commercialization of the new ingredient to reach consumers outside of Japan by leveraging its own portfolio, application expertise, and commercial footprint.
“We are very pleased to partner with Kerry, a world leader in the development of taste and nutrition solutions for the food, beverage and supplement markets,” said Dr. Lekh Juneja, chairman and CEO of Kameda Seika. “Kerry is an ideal partner, with deep expertise in science backed branded ingredients, including probiotics and postbiotics, and their footprint of dedicated innovation and application centers of excellence across the globe. We are extremely proud of the development of Lactobacillus K-1, which has already demonstrated many health benefits in clinical trials. We look forward to this partnership with Kerry, who will bring this postbiotic to a much larger global audience.”
Lactobacillus K-1 postbiotic has been supported by a randomized, double-blind, clinical study to support digestive health, appearing in Bioscience of Microbiota, Food, and Health.
Postbiotics, the byproducts of inanimate microorganisms, offer similar benefits as probiotics, but are more heat- and acid-stable.
Kameda Seika is a global rice cracker company which has researched rice-based lactobacillus for over 25 years. The company’s postbiotic ingredient has been evidenced to improve measures of digestive and skin health and can be used in a variety of food, beverages, and supplements. Kerry will drive the commercialization of the new ingredient to reach consumers outside of Japan by leveraging its own portfolio, application expertise, and commercial footprint.
“We are very pleased to partner with Kerry, a world leader in the development of taste and nutrition solutions for the food, beverage and supplement markets,” said Dr. Lekh Juneja, chairman and CEO of Kameda Seika. “Kerry is an ideal partner, with deep expertise in science backed branded ingredients, including probiotics and postbiotics, and their footprint of dedicated innovation and application centers of excellence across the globe. We are extremely proud of the development of Lactobacillus K-1, which has already demonstrated many health benefits in clinical trials. We look forward to this partnership with Kerry, who will bring this postbiotic to a much larger global audience.”
Lactobacillus K-1 postbiotic has been supported by a randomized, double-blind, clinical study to support digestive health, appearing in Bioscience of Microbiota, Food, and Health.
